RO4917838 for the negative symptoms of schizophrenia -Study NN25310

• Research type

  Research Study

• Full title

  A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period

• IRAS ID

  63344

• Contact name

  John Geddes

• Sponsor organisation

  F Hoffman-La Roche Ltd

• Eudract number

  2010-020370-42

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This is a phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to determine whether the experimental drug RO4917838 is effective and safe in treating stable patients with persistent, predominant negative symptoms of schizophrenia who are being treated with antipsychotics followed by a 28 week, double-blind treatment period.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  10/H0606/69

• Date of REC Opinion

  6 Jan 2011

• REC opinion

  Further Information Favourable Opinion